Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ORIC

ORIC Pharmaceuticals Inc

10.91

Aug 04 • 8:31 AM ET +0.31 (2.92%)

Healthcare Biotechnology USA Small NASD

Aug 03, 6:45 PMORIC Pharmaceuticals launches Himalayas-1 global Phase 3 mCRPC trial with Bayer darolutamide supply and posts Q2 2026 EPS -0.38, missing estimates

Peers: RCUS IDYA TNGX NUVL CGON KYMR RYTM BMRN INCY KRYS

| Held by: XBI VTI IWM VXF IWN IBB VTWO SCHA DFAS FESM

Scroll to Statements

Index	RUT
Market Cap	1.13B
Enterprise Value	867.95M
Income	-140.35M
Sales	0.00M
Book/sh	3.68
Cash/sh	2.56
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	104
IPO	Apr 24, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.97
P/C	4.27
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	13.19
Current Ratio	13.19
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.35
EPS next Y	-1.63
EPS next Q	-0.38
EPS this Y	-1.62%
EPS next Y	-8.92%
EPS next 5Y	-4.85%
EPS past 3/5Y	13.10% 15.18%
Sales past 3/5Y	- -
EPS Y/Y TTM	23.91%
Sales Y/Y TTM	-
EPS Q/Q	17.45%
Sales Q/Q	-
Earnings	Aug 03 AMC
EPS/Sales Surpr.	-5.76% -

Insider Own	39.40%
Insider Trans	-0.16%
Inst Own	77.21%
Inst Trans	-0.82%
ROA	-37.35%
ROE	-39.80%
ROIC	-36.81%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.14%
SMA50	11.88%
SMA200	3.40%
Trades

Shs Outstand	103.64M
Shs Float	62.74M
Short Float	35.15%
Short Ratio	13.07
Short Interest	22.05M
52W High	14.93 -26.93%
52W Low	7.23 50.90%
Volatility	7.59% 7.24%
ATR (14)	0.74
RSI (14)	51.87
Beta	0.97
Rel Volume	0.05
Avg Volume	1.69M
Volume	4,351

Perf Week	-8.40%
Perf Month	0.00%
Perf Quarter	13.29%
Perf Half Y	-2.24%
Perf YTD	33.37%
Perf Year	11.95%
Perf 3Y	42.24%
Perf 5Y	-31.38%
Perf 10Y	-
Recom	1.20
Target Price	20.69
Prev Close	10.60
Price	10.91
Change	2.92%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-12-26	Resumed	Stifel	Buy	$14
May-15-26	Upgrade	Goldman	Neutral → Buy	$15
Jan-07-26	Initiated	Piper Sandler	Overweight	$22
Nov-20-25	Initiated	Evercore ISI	Outperform	$25
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-04-25	Resumed	Guggenheim	Buy	$18
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$15
Oct-31-24	Initiated	Wells Fargo	Overweight	$20
Sep-06-24	Initiated	Stifel	Buy	$20
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform	$8
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy	$16
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy	$15
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform	$14
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral	$22 → $7

Show Previous Ratings

Aug-03-26 04:05PM	ORIC Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates (GlobeNewswire)
Jul-20-26 08:30AM	ORIC Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 (GlobeNewswire)
Jul-14-26 04:05PM	ORIC Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA (Darolutamide), Supported by Clinical Collaboration with Bayer (GlobeNewswire) +5.59%
Jul-02-26 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.89% -6.27%
Jun-05-26 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.48%
04:05PM	Loading…
May-27-26 04:05PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-04-26 04:05PM	ORIC Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates (GlobeNewswire)
May-01-26 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-17-26 04:05PM	ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +5.08%
Apr-03-26 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-26 08:20AM	Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM (BioPharma Dive) +18.93%
Apr-01-26 04:05PM	Oric Shares Fall 40% as Cancer-Drug Data Falls Short of Expectations (The Wall Street Journal) -41.00%
Mar-31-26 04:05PM	ORIC Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile (GlobeNewswire)
Mar-27-26 08:30AM	ORIC Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC (GlobeNewswire)
Mar-17-26 05:01PM	ORIC Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -10.02%
10:38AM	Loading…
Mar-10-26 10:38AM	Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained (24/7 Wall St.) +8.07%
Mar-09-26 09:55AM	After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright (Zacks) -15.03%
Mar-06-26 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-26 04:16AM	Oric Pharmaceuticals Teases Key 2026 Catalysts, Phase 3 Plans for Prostate and Lung Cancer Drugs (MarketBeat)
Feb-26-26 09:55AM	Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade (Zacks)
Feb-25-26 10:55AM	Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright (TipRanks)
Feb-23-26 04:05PM	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates (GlobeNewswire) +5.40% +14.60%
Feb-14-26 02:04PM	Oric Pharmaceuticals Highlights 2025 Milestones at Guggenheim, Targets Phase 3 Prostate Trial in 1H25 (MarketBeat)
Feb-06-26 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-26 04:01PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.13%
Jan-21-26 05:59AM	Piper Sandler Puts its Weight Behind 2 Strong Buy Cancer Stocks (TipRanks) +5.42%
Jan-15-26 01:23PM	Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 (Investor's Business Daily)
Jan-14-26 10:52AM	Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff (PR Newswire) +10.95%
Jan-12-26 08:30AM	ORIC Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones (GlobeNewswire)
Jan-06-26 04:05PM	ORIC Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.63%
11:11PM	Loading…
Dec-15-25 11:11PM	ORIC Pharmaceuticals (ORIC) Surges as Intriguing ESMO Asia Data for Enozertinib Prompts Wells Fargo to Assign Higher Value (Insider Monkey)
Dec-05-25 08:00PM	ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 (GlobeNewswire)
04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:00AM	ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 (GlobeNewswire)
Dec-04-25 09:45PM	ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 (GlobeNewswire)
Dec-03-25 04:01PM	ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 (GlobeNewswire)
Dec-01-25 08:00AM	ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025 (GlobeNewswire) -6.14%
Nov-24-25 04:05PM	ORIC Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-18-25 12:00PM	Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-13-25 04:10PM	ORIC Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates (GlobeNewswire)
04:05PM	ORIC Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety (GlobeNewswire)
Nov-07-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 04:00PM	ORIC Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor (GlobeNewswire)
Nov-04-25 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-27-25 08:30AM	ORIC Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors (GlobeNewswire)
Oct-22-25 09:24AM	BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now? (Zacks)
Sep-17-25 01:45PM	Oric Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-05-25 04:05PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-27-25 04:05PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:05PM	ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer (GlobeNewswire)
Aug-12-25 04:05PM	ORIC Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates (GlobeNewswire)
Aug-01-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-25 09:55AM	Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Jul-11-25 12:00PM	Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy? (Zacks)
Jul-03-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-19-25 12:00PM	All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy (Zacks)
09:55AM	Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect? (Zacks)
Jun-13-25 12:00PM	What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now? (Zacks)
11:30AM	JPMorgan biotech/pharma analysts hold analyst/industry conference call (TipRanks)
Jun-06-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.79%
Jun-02-25 09:55AM	Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know (Zacks)
May-29-25 11:53AM	ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study (Zacks) +33.50%
12:09AM	ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials (Insider Monkey)
May-28-25 04:05PM	ORIC Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC (GlobeNewswire)
04:05PM	ORIC Pharmaceuticals Announces $125 Million Private Placement Financing (GlobeNewswire)
May-27-25 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -8.98%
08:00AM	ORIC Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC (GlobeNewswire)
May-05-25 04:05PM	ORIC Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates (GlobeNewswire) -11.58%
May-02-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-25 04:30PM	ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +11.10%
Apr-22-25 09:15AM	ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech (Seeking Alpha) +7.19%
07:30AM	ORIC Pharmaceuticals: Looking To The Horizon With Pivotal Study Plans (Seeking Alpha)
Apr-16-25 11:09AM	Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -6.94%
Apr-04-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.22% -5.94%
Mar-31-25 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.12%
Mar-25-25 04:30PM	ORIC Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -8.41% -13.33%
Mar-07-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-25-25 04:15PM	ORIC Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones (GlobeNewswire) +6.88%
Feb-18-25 04:05PM	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates (GlobeNewswire) -6.10%
Feb-07-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.33%
Jan-27-25 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.85%
Jan-15-25 10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire) +9.69%
Jan-14-25 08:35AM	Oric Pharmaceuticals announces clinical supply agreement with Janssen (TipRanks) +15.23%
Jan-13-25 08:05AM	ORIC Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones (GlobeNewswire) +8.04%
08:00AM	ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations (GlobeNewswire)
Jan-06-25 04:15PM	ORIC Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.82%
Jan-03-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-25-24 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 04:05PM	ORIC Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
Nov-04-24 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-01-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-23-24 07:00AM	ORIC Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-09-24 04:15PM	ORIC Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-04-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-17-24 12:00PM	OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration (PR Newswire)
Sep-14-24 05:35PM	ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-06-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-24 04:05PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.04%
Aug-12-24 04:05PM	ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates (GlobeNewswire) +6.76%
Aug-05-24 04:15PM	ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs (GlobeNewswire) -8.65%

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

FounderDr. Richard A. Heyman Ph.D.

M.D.Dr. Jacob M. Chacko M.B.A.

M.B.A.Mr. Dominic G. Piscitelli CPA

M.S.Dr. Pratik S. Multani M.D.

M.D.Dr. Charles L. Sawyers B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heyman Richard A.	Director	Jul 24 '26	Option Exercise	1.60	3,500	5,600	45,300	Jul 28 04:15 PM
Heyman Richard A.	Director	Jul 24 '26	Sale	12.02	7,000	84,140	38,300	Jul 28 04:15 PM
Heyman Richard A.	Director	Jul 24 '26	Sale	12.02	6,100	73,322	206,672	Jul 28 04:15 PM
Heyman Richard A.	Director	Jul 06 '26	Sale	12.00	300	3,600	212,772	Jul 08 04:35 PM
Richard A, Heyman	Director	Jul 06 '26	Proposed Sale	12.00	7,000	84,000		Jul 06 04:27 PM
Richard A, Heyman	Director	Jul 06 '26	Proposed Sale	12.00	6,400	76,800		Jul 06 04:27 PM
Piscitelli Dominic	Chief Financial Officer	Feb 24 '26	Option Exercise	4.36	52,000	226,720	120,148	Feb 26 04:47 PM
Piscitelli Dominic	Chief Financial Officer	Feb 24 '26	Sale	13.51	52,000	702,686	68,148	Feb 26 04:47 PM
Dominic Piscitelli	Officer	Feb 24 '26	Proposed Sale	13.50	52,000	702,000		Feb 24 04:08 PM
Heyman Richard A.	Director	Jan 16 '26	Sale	12.00	3,500	42,016	41,800	Jan 20 07:19 PM
Heyman Richard A.	Director	Jan 16 '26	Sale	12.00	3,200	38,415	213,072	Jan 20 07:19 PM
Richard A, Heyman	Director	Jan 16 '26	Proposed Sale	12.00	6,400	76,800		Jan 16 04:57 PM
Richard A, Heyman	Director	Jan 16 '26	Proposed Sale	12.00	7,000	84,000		Jan 16 04:43 PM
Multani Pratik S	Chief Medical Officer	Dec 15 '25	Option Exercise	0.00	29,333	0	78,869	Dec 17 07:21 PM
Multani Pratik S	Chief Medical Officer	Dec 16 '25	Sale	9.06	10,720	97,129	68,149	Dec 17 07:21 PM
Piscitelli Dominic	Chief Financial Officer	Dec 15 '25	Option Exercise	0.00	29,333	0	78,868	Dec 17 07:19 PM
Piscitelli Dominic	Chief Financial Officer	Dec 16 '25	Sale	9.06	10,720	97,127	68,148	Dec 17 07:19 PM
Chacko Jacob	PRESIDENT AND CEO	Dec 15 '25	Option Exercise	0.00	83,666	0	615,085	Dec 17 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Dec 16 '25	Sale	9.06	33,374	302,368	581,711	Dec 17 07:18 PM
Piscitelli Dominic	Officer	Dec 16 '25	Proposed Sale	9.06	10,720	97,128		Dec 16 09:46 PM
Multani Pratik S	Officer	Dec 16 '25	Proposed Sale	9.06	10,720	97,129		Dec 16 09:44 PM
Chacko Jacob	Officer	Dec 16 '25	Proposed Sale	9.06	33,374	302,370		Dec 16 09:42 PM
Kunkel Lori Anne	Director	Dec 08 '25	Option Exercise	7.90	10,000	79,000	84,200	Dec 09 05:35 PM
Kunkel Lori Anne	Director	Dec 04 '25	Option Exercise	3.75	5,534	20,752	74,200	Dec 05 05:47 PM
Piscitelli Dominic	Chief Financial Officer	Oct 06 '25	Option Exercise	4.36	11,000	47,960	59,317	Oct 08 05:37 PM
Piscitelli Dominic	Chief Financial Officer	Oct 06 '25	Sale	14.52	11,000	159,719	48,317	Oct 08 05:37 PM
Chacko Jacob	PRESIDENT AND CEO	Oct 06 '25	Sale	12.32	37,461	461,520	531,419	Oct 08 05:35 PM
Dominic Piscitelli	Officer	Oct 06 '25	Proposed Sale	14.50	50,000	725,000		Oct 06 04:22 PM
Heyman Richard A.	Director	Oct 03 '25	Option Exercise	1.69	32,800	55,591	45,300	Oct 03 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Oct 01 '25	Sale	12.05	53,001	638,805	568,880	Oct 02 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Sep 30 '25	Sale	12.01	34,538	414,750	621,881	Oct 02 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Sep 22 '25	Sale	10.80	125,000	1,349,938	656,419	Sep 24 04:30 PM
Jacob Chacko	Director	Sep 22 '25	Proposed Sale	10.50	250,000	2,625,000		Sep 22 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ORIC

ORIC Pharmaceuticals Inc

Upgrade your Finviz experience